Chapter. Contents Breast Cancer Adjuvant Epirubicin weekly. Docetaxel Copy No:
|
|
- Rosemary Smith
- 5 years ago
- Views:
Transcription
1 Chapter 2: Breast Cancer Contents Chapter 2: Breast Cancer... 1 Breast Cancer... 2 Adjuvant Epi-CMF... 2 FEC / docetaxel... 3 FEC AC/EC/TC... 4 (neo) adjuvant HER2 positive: TCarboH... 6 NCRI recommendations for cardiac monitoring... 7 Neo-adjuvant... 8 AC/ECC... 8 Docetaxel... 9 Taxane allergy... 9 *Paclitaxel albumin (Abraxane )... 9 Advanced disease Doxorubicin AC/ECC Doxorubicin weekly Epirubicin weekly Docetaxel Paclitaxel Docetaxel / capecitabine Paclitaxel / gemcitabine Capecitabine Vinorelbine Gemcitabine / carboplatin Management of patients with HER2 positive cancers / pertuzumab / docetaxel 1 st line regimen only *Lapatinib and capecitabine Other CDF approved therapy *Bevacizumab *Everolimus and exemestanee Bone directed therapy Denosumab Bisphosphonate Page 1 of 24
2 Breast Cancer Adjuvant Epi-CMF Epi-CMF Epi 4 cycles n Epirubicin 100mg/m 2 IV bolus Followed by 4 cycles CMF Epi-CMF CMF Days 1 to 14 Every 28 Days Cyclophosphamide 100mg/m 2 4 cycles Orally, daily for 14 days in divided doses Days 1 and 8 Methotrexatee 40mg/m 2 IV bolus Days 1 and 8 Fluorouracill 600mg/m 2 IV bolus For patients unable to tolerate oral cyclophospha amide substitute: IV cyclophosphamide 600mg/m 2 days 1 and 8 Folinic acid rescue is not normally equired unless patient develop signs of methotrexate toxicity, add orally 15mg 6 hourly x 6 dosess starting 24 hours post methotrexatee with subsequent cycless LV ejection fraction prior to cycle 1 if history off cardiac problems butt methotrexate is hazardous in the presence of renal insufficiency, not required on day 8 Standard FBC limits for administration apply Page 2 of 24
3 FEC / docetaxel This protocol is available for node positive or high risk node negative patients. Patients should receive primary prophylaxis withh pegfilgrastim after each cycle FEC/docetaxel FEC Fluorouracil Epirubicin Cyclophosphamide 500mg/m 2 100mg/m 2 500mg/m 2 3 cycles n IV bolus IV bolus IV bolus Day 2 Pegfilgrastim 6mgg SC injection Followed by 3 cycles docetaxel FEC/docetaxel Docetaxel Dexamethasone 8mg BD Docetaxel 100mg/m h 3 cycles Orally for 3 days, commencing 24 hours before docetaxel IV infusion Day 2 Pegfilgrastim 6mg SC injection LV ejection fraction prior to cycle 1 if history off cardiac problems Standard FBC limits for administration apply For patients unable to tolerate 3 weekly docetaxel, weekly paclitaxel may be used as an alternative Weekly paclitaxel Every 7 days Chlorphenamine Dexamethasone Ranitidine Paclitaxel 10mg 8mgg 50mg 80mg/ /m 2 12 weeks Reducing to 4mg from week 2 Page 3 of 24
4 FEC100 As alternative to Epi-CMF regimen FEC 6 cycless Fluorouracil 500mg/m 2 Epirubicin 100mg/m 2 Cyclophosphamide 500mg/m 2 Day 2 Pegfilgrastim 6mgg SC injection LV ejection fraction prior to cycle 1 if history off cardiac problems Standard FBC limits for administration apply AC/EC/TC AC 4 cycless Doxorubicin 60mg/ /m 2 Cyclophosphamide 600mg/m 2 OR EC 4 cycless Epirubicin 90mg/ /m 2 Cyclophosphamide 600mg/m 2 AC for 4 cycles has been shown to be equivalent to 6 cycles of CMF Page 4 of 24
5 In patients at significant risk of cardiac problems: TC TC 4 6 cycles Dexamethasone Docetaxel 8mg BD 75mg/ /m 2 Orally for 3 days, commencing 24 hours before docetaxel Cyclophosphamide 600mg/m 2 LV ejection fraction prior to cycle 1 if history off cardiac problems, standard FBC limits for administration apply (neo) adjuvantt For patients with HER2 positive cancers (IHC 3+ + and / or FISH positive): Non-metastatic potentially operable primary invasive breast cancer Given after completion of (neo) adjuvant anthracyclines, it can be givenn in combination with trastuzumab ECOG PS 0 or 1 Baseline LVEF normal after completing anthracycline chemotherapy, no n serious cardiac illness Subcutaneous Herceptin Herceptin SC 600mg 18 cycles Subcutaneous injectionn over 2 to 5 minutes 18 cycles Cycle 1 8mg/kg IV infusion over 90 minutes Subsequent IV infusion over 60 minutes, reduced to t 30 mins if 6mg/kg cycles tolerated May be given concurrently with docetaxel in FEC/docetaxel regimen Stop at any time if CCF develops (see NCRI recommendations for cardiac monitoring) Page 5 of 24
6 In patients at significant risk of cardiac problems: HER2 positive: TCarboH TCarboH Dexamethasone Docetaxel 8mg BD 75mg/ /m 2 6 cycles Orally for 3 days, d commencing 24 hours before docetaxel Carboplatin AUC6 Day 2 Pegfilgrastim 6mgg SC injection Cycle 1 Subsequent cycles (2 to 6) 8mg/kg 6mg/kg Loading dose IVV over 90 mins Subsequent doses IV overr 60mins, then reduce to 30 mins if tolerated Continue with trastuzumab maintenance to 18 cycles in total. Subcutaneous Herceptin Subsequent cycles Herceptin SC (6 to 18) 600mg To complete 18 cycles Subcutaneouss injection over 2 to 5 minutes OR To complete 18 cycles Subsequent cycles (6 to 18) 6mg/kg IV infusion over 30 mins Page 6 of 24
7 NCRI recommendations for cardiac monitoring Ref: British Journal of Cancer : Page 7 of 24 Authorised by: Dr Susan O Reilly
8 Neo-adjuvant Indication / treatment plan Patients with locally advanced disease or to alloww less radical surgery in patients withh operable tumours. Options include six cycles of EC/AC or four cycles EC/AC followed by four cycles docetaxel at 100mg/m 2 HER-2 positive patients may commence trastuzumab following completion of anthracycline based treatment i.e. concurrently with docetaxel if this is being given providedd LVEF normal after completion of the anthracycline. Patients should then have the remaining 14 cycles of trastuzumab as adjuvant treatment. AC/EC AC Upto 6 cycles n Doxorubicin 60mg/ /m 2 IV bolus Cyclophosphamide 600mg/m 2 IV bolus Day 2 Pegfilgrastim 6mgg SC injection OR EC Upto 6 cycles n Epirubicin 90mg/ /m 2 IV bolus Cyclophosphamide 600mg/m 2 IV bolus Day 2 Pegfilgrastim 6mgg SC injection LV ejection fraction prior to cycle 1 if history off cardiac problems Standard FBC limits for administration apply Page 8 of 24
9 Docetaxel Docetaxel 4 cycles Dexamethasone Docetaxel 8mg BD 100mg/m 2 Orally for 3 days, d commencing 24 hours before docetaxel Day 2 Pegfilgrastim 6mgg SC injection Standard FBC limits for administration apply For patients unable to tolerate 3 weekly docetaxel, weekly paclitaxel may be used as an alternative Weekly paclitaxel Every 7 days Chlorphenamine Dexamethasone Ranitidine Paclitaxel 10mg 8mgg 50mg 80mg/ /m 2 12 weeks Reducing to 4mg from week 2 Taxane allergy *Paclitaxel albumin (Abraxane ) Paclitaxell albumin Paclitaxell albumin 260mg/m 2 Until disease progression IV infusion over 30 minutes Consider if no longer safe to continue with paclitaxel or docetaxel. Patients may be able to receive Abraxane with premedication and appropriate precautions. Page 9 of 24
10 Criteria: Adjuvant breast cancer Situations where taxanes are Normal FBC limits for administration apply Page 10 of 24
11 Advancedd disease Doxorubicin Doxorubicin single agent 6 cycless Doxorubicin 75mg/ /m 2 AC/EC AC Upto 6 cycles Doxorubicin 60mg/ /m 2 Cyclophosphamide 600mg/m 2 OR EC Upto 6 cycles Epirubicin 90mg/ /m 2 Cyclophosphamide 600mg/m 2 LV ejection fraction prior to cycle 1 if history off cardiac problems Normal FBC limits for administration apply Page 11 of 24
12 For patients with compromised liver or marrow function due to tumour infiltration Doxorubicin weekly Doxorubicin weekly Every 7 days Doxorubicin 20mg/m 2 Usually 6 to 8 weeks, increasing to 21 day cycles where possible. IV bolus Maximum doxorubicin total dose 450mg/m 2 Epirubicin weekly Epirubicin weekly Every 7 days Epirubicin 20 to 30mg/ /m 2 Usually 6 to 8 weeks initially IV bolus Ensure normal renal function priorr to cycle 1 and repeat during subsequent cycles if clinically Patients with abnormal hepatic function shouldd be treated cautiously LV ejection fraction prior to cycle 1 if history off cardiac problems. Normal limits for administration apply with the exception that for patients with marrow infiltrationn treatment may be continued at lower platelett and neutrophil counts at treating physician discretion. Docetaxel Docetaxel 3 cycles Dexamethasone Docetaxel 8mg BD 75 to 100mg/m 2 n Orally for 3 days, commencing 24 hours before docetaxel Page 12 of 24
13 Normal FBC limits for administration apply Paclitaxel Weekly paclitaxel Every 7 days Chlorphenamine Dexamethasone Ranitidine Paclitaxel 10mg 8mgg 50mg 80mg/ /m 2 Until disease progression Reducing to 4mg from week 2 Paclitaxel weekly: for patients with compromised d liver or marrow functionn who have previously received anthracyclines. investigations Ensure normal renal function priorr to cycle 1 and repeat during subsequent cycles if clinically Patients with abnormal hepatic function shouldd be treated cautiously. Normal limits for administration apply with the exception that for patients with marrow infiltrationn treatment may be continued at lower platelett and neutrophil counts at treating physician discretion. Docetaxel / capecitabine Docetaxel / capecitabine Dexamethasone Docetaxel to 14 Capecitabine 8mg BD 75mg/ /m mg/mm 2 BD Upto 6 cycles n Orally for 3 days, commencing 24 hours before docetaxel Twice daily (morning and evening) orally, for 14 dayss followed byy 7 days off NB Capecitabine is contra-d when creatinine clearance is below 30mL/min. See capecitabine renal function recommendations (chapter 1) Criteria PS 0-1 NB very fit patients only where rapid symptomatic control is required Recurrent following adjuvant anthracycline therapy Page 13 of 24
14 Normal FBC limits for administration apply Paclitaxel / gemcitabine Paclitaxell / gemcitabine Chlorphenamine 10mg Upto 6 cycles Dexamethasone 16mg Ranitidine 50mg Paclitaxel 175mg/m 2 IV infusion overr 3 hours Gemcitabine 1250mg/m 2 IV infusion over 30 minutes Day 8 Gemcitabine 1250mg/m 2 IV infusion over 30 minutes Criteria PS 0-1 NB very fit patients only Recurrent following adjuvant anthracycline therapy Normal FBC limits for administration apply Capecitabine Capecitabine orally Days 1 to 14 Capecitabine 1000 to 1250mg/m Upto 6 cycles n Tw wice daily (morning and evening) orally, for 14 dayss followed byy 7 days off In elderly patients consider a starting dose of 850mg/m 2 BD Page 14 of 24
15 can be reduced further to mg/m 2 twice daily for 14 days followed by 7 days off if heavily pre- treated or poorer PS NB Capecitabine is contra-d when creatinine clearance is below 30mL/min See capecitabine renal function recommendations (chapter 1) Criteria Failed or unsuitable for anthracycline and/or taxane PS 0-2 Normal FBC limits for administration apply *Eribulin Eribulin Until disease progression Eribulin 1.23 mg/m 2 IV infusion over 2 too 5 minutes Day 8 Eribulin 1.23 mg/m 2 IV infusion over 2 too 5 minutes *NB available via the Cancer s fund CDF Criteria (as at 23 rd September 2013) The treatment of advanced breast cancer wheree all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Advancedd breast cancer 3. At least 2 prior chemotherapy regimens for advanced disease Impaired liver function due to metastases: The recommended dose of eribulin in patients with mild hepatic impairment (Child-Pugh A) is 0.97 mg/m 2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. The recommended dose of eribulin in patients with moderate hepatic c impairment (Child-Pugh B) is 0.62 mg/m 2 administered intravenously over 2 to 5 minutes on Dayss 1 and 8 of a 21-day cycle. Page 15 of 24
16 Normal FBC limits for administration apply Vinorelbinee Vinorelbine intravenous Upto 6 cycles Vinorelbine 25 to 30mg/m 2 IVV infusion over 5 mins Day 8 Vinorelbine Maximum single dose 60mg 25 to 30mg/m 2 IVV infusion over 5 mins Vinorelbine oral Upto 6 cycles Vinorelbine 60 to 80mg/m 2 Orally O as a single dose Day 8 Vinorelbine 60 to 80mg/m 2 Orally O as a single dose Maximum dose 120mg for 60mg/m 2 dose and 160mg for 80mg/m 2 dose Reassess after every 2 cycles, maximum 6 cycles Criteria: WHO performance status 0-1 Endocrine resistant Prior alkylating agent therapy Normal FBC limits for administration apply Page 16 of 24
17 Gemcitabine / carboplatin Gemcitabine / carboplatin Carboplatin Gemcitabine Day 8 Gemcitabine AUC mg/m mg/m 2 Course C length Upto 6 cycles IV infusion over 30 minutes IV infusion over 30 minutes Ensure normal hepatic function prior to cycle 1 and repeat during subsequent cycles if clinically NB: transaminases may rise during treatment Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if clinically Normal FBC limits for administration apply, if outside limits on day 8 then omit treatment and re-start chemotherapy again on day 1 as scheduled For patients with significant previous chemotherapy treatment or underlying thrombocytopenia the split dose regimen should be considered Gemcitabine / carboplatin split dose Carboplatin Gemcitabine AUC mg/m Course C length Upto 6 cycles IV infusion over 30 minutes Day 8 Carboplatin AUC 2.5 Day 8 Gemcitabine 1250mg/m 2 IV infusion over 30 minutes Cycle interval can be increased to 28 days if clinically Ensure normal hepatic function prior to cycle 1 and repeat during subsequent cycles if clinically NB: transaminases may rise during treatment Calculate or measure creatinine clearance prior to first cycle and before subsequent cycles if clinically Page 17 of 24
18 , normal FBC limits for administration apply Page 18 of 24
19 Management of patients with HER2 positive cancers Subcutaneous Herceptin (trastuzumab) Herceptin SC 600mg Until disease progression Subcutaneous injectionn over 2 to 5 minutes OR Until disease progression Cycle 1 Subsequent cycles 8mg/kg 6mg/kg IV infusion over 90 minutes IV infusion over 60 minutes, reduced to t 30 mins if tolerated Criteria: Strongly HER2 positive (HER2 3+ by IHC or FISH positive) given together with non-anthracycline based chemotherapyy or as a single agent. LVEF: baseline ECHO/MUGA and repeated as algorithm in adjuvant section. Page 19 of 24
20 / pertuzumab / docetaxel 1 st line regimen only / pertuzumab / docetaxel Until disease progression n Cycle 1 Cycle 1 Dexamethasone 8mg BD 8mg/kg Orally for 3 days, commencing 24 hours before docetaxel IV infusion over 90 minutes Cycle 1 Pertuzumab* 840mg Cycle 1 Cycle 2 Cycle 2 onwards Cycle 2 onwards Cycle 2 to 6 Docetaxel Dexamethasone Pertuzumab* Docetaxel 75mg/ /m 2 8mg BD 6mg/kg 420mg 75mg/ /m 2 Orally for 3 days, commencing 24 hours before docetaxel IV infusion 30 to 60 minutes IV infusion over 30 to 60 minutes Docetaxel dose may be increased to 100mg/m 2 if well tolerated from cycle 2 onwards. and pertuzumab continue after docetaxel course is completed. to remain intravenous administration. Criteria: Strongly HER2 positive (HER2 3+ by IHC or FISH positive) LVEF: baseline ECHO/MUGA and repeated as algorithm (in adjuvant section). Review LFTs at each cycle If unacceptable toxicity from docetaxel at reduced dose of 60mg/m 2 then paclitaxel may be used as alternative. If the time between 2 pertuzumab doses is 6 weeks or more than a re-loading dose of 840mg needs to be administered. *NB available via the Cancer s fund CDF Criteria (as at 23 rd September 2013) The first line treatment of locally advanced or metastatic breast cancer where w all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Locally advanced or metastatic breast cancer 3. HER-2 3+ or FISH positive 4. PS Any adjuvant HER2 therapy should have beenn completed more than 12 months prior to metastatic diagnosis 6. No prior treatment with chemotherapy of HER2 therapy for metastatic disease 7. To be given as first line treatmentt in combination with docetaxel and trastuzumab NOTE: not to be used beyond first disease progression Page 20 of 24
21 *Lapatinib and capecitabine Lapatinib and capecitabine Days 1 to 14 Capecitabine Daily Lapatinib Until disease progression n 1000 mg/ /m 2 Tw wice daily (morning and evening) orally, for 14 dayss followed byy 7 days off 1250mgg Daily, continuously NB see capecitabine renal function recommendations (chapter 1) Capecitabine may be reduced to 850mg/m 2 twice daily for 14 days followed by 7 days off if heavily pre- treated or poorer PS For some responding patients continuing with lapatinib alone may be thee right approach if capecitabine toxicity becomes unacceptable. Normal FBC limits for administration apply *NB available via the Cancer s fund CDF Criteria (as at 23 rd September 2013) The treatment of advanced breast cancer wheree all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Progressing advanced or metastatic breast cancer 3. HER-2 over-expression 4. Previous treatment with anthracyclines or anthracyclines contra-indica ated 5. Previous treatment with taxanes 6. Previous treatment with trastuzumab in the metastatic setting 7. Use in combination with capecitabine Page 21 of 24
22 Other CDF approved therapy *Bevacizumab Bevacizumab Every 14 Days Bevacizumab 10mg/ /kg Until disease progression IV infusion over 90 minutes for first infusion, then 60 and 30 minutes as tolerated To be given in combination with paclitaxel *NB available via the Cancer s fund CDF Criteria (as at 23 September 2013) The treatment of advanced breast cancer wheree all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. Advancedd Breast Cancer 3. Triple negative disease (ER, PR, and HER2 negative) 4. a) 1st line indication OR b) 2nd line indication 5. To be given in combination with paclitaxel Proteinuria monitoring BP at each cycle, normal FBC limits for administration apply *Everolimus and exemestane Everolimus and exemestane Continuous, supplied every 28 days Daily Everolimus 10mg Until disease progression / toxicity Orally, daily Daily Exemestane 25mg Orally, daily (may be obtained via GP) *NB available via the Cancer s fund CDF Criteria (as at 23 rd September 2013) Page 22 of 24
23 The treatment of advanced breast cancer wheree all the following criteria are met: 1. Application made by and first cycle of systemic anti-cancer therapy to be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy 2. ER +ve, HER2 ve metastatic breast cancer 3. No symptomatic visceral disease 4. In combination with exemestane 5. Previous treatment with a non-steroidal aromatase inhibitor 6. No previous treatment with exemestane for metastatic breast cancer 7. No more than one line of chemotherapy for the treatment of advanced breast cancer Normal FBC limits for administration apply Blood glucose and triglycerides at baseline, then as Page 23 of 24
24 Bone directed therapy Denosumab Denosumab Every 28 Days Continuous Denosumab 120mg Subcutaneouss injection Daily Adcal D3 1 to 2 daily Orally daily Calcium supplements: Supplementation of at least 500 mg calcium and 4004 IU vitamin D daily is required in all patients, unless hypercalcaemia is present. Patients should have their serum calcium measured every four weeks and the dose of Adcal D3 tablets adjusted as necessary. Bisphosphonate Zoledronic acid Every 28 Days (range 21 42) Zoledronic acid 4mg* Continuous n IV infusion over 15 minutes Daily Adcal D3 1 to 2 daily Orally daily Criteria: Performance status 0-2 Symptomatic / extensive bone metastases Calcium supplements: Supplementation of at least 500 mg calcium and 4004 IU vitamin D daily is required in all patients, unless hypercalcaemia is present. Patients should have their serum calcium measured every four weeks and the dose of Adcal D3 tablets adjusted as necessary. *Renal impairment Cr clearance >60 4.0mg mg mg mg < 30 no treatment Cockcroft and Gault formula to be used for calculating creatinine clearance, see chapter 1 Serum creatinine should be repeated every 4 weeks and if it rises significantly duringg treatment zoledronic acid should be witheld until the creatinine has returned to within 10% of the t baseline prior to starting. Page 24 of 24
CCC Chemotherapy Protocols V9.0
CCC Chemotherapy Protocols V9.0 General observations 3 Breast cancer 5 Gastrointestinal cancer Oesophagus 17 Gastric 19 Pancreas 22 Cholangiocarcinoma 24 Hepatocellular carcinoma 25 Neuroendocrine tumours
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationFEC-T plus trastuzumab & pertuzumab
Page 1 of 5 Indication Treatment Intent Frequency and number of cycles Monitoring parameters pre-treatment The neoadjuvant treatment of locally advanced, inflammatory or early HER2 positive breast cancer
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationFEC-D with HP Fluorouracil, Epirubicin, Cyclophosphamide, Followed by Docetaxel, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Approved for use in: Neoadjuvant breast cancer: The neoadjuvant treatment of HER2 positive locally advanced, inflammatory or early breast cancer at high risk of recurrence Interim CDF funding from November
More informationTCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol
Systemic Anti Cancer Treatment Protocol TCHP Docetaxel, Carboplatin, Trastuzumab, Pertuzumab Neoadjuvant Protocol PROTOCOL REF: MPHATCHP (Version No: 1.0) Approved for use in: Neoadjuvant breast: The neoadjuvant
More informationEC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen
y Systemic Anti Cancer Treatment Protocol EC (Epirubicin Cyclophosphamide) Adjuvant/Neo-adjuvant regimen PROTOCOL REF: MPHAECANBR (Version No: 1.0) Approved for use in: ER positive, HER2 negative ( Luminal
More informationPertuzumab, Herceptin (Trastuzumab) and Docetaxel Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Cycle One Loading Doses Day 1 Paracetamol 1g Oral Day 1 Ondansetron 8mg Oral /Slow bolus/15 min infusion Day 1 Pertuzumab 840mg IV Infusion Pertuzumab and Herceptin can be
More informationE 90 C followed by Weekly Paclitaxel
E 90 C followed by Weekly Paclitaxel Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationPaclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen
Systemic Anti Cancer Treatment Protocol Paclitaxel/Carboplatin with dose dense EC Neoadjuvant Regimen PROTOCOL REF: MPHAPCECBR (Version No: 1.0) Approved for use in: Neoadjuvant treatment of operable,
More informationSustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA
Sustained benefits for women with HER2-positive early breast cancer JORGE MADRID BIG GOCCHI PROTOCOLO HERA The fascinating history of Herceptin 1981 1985 1987 1990 1992 1998 2000 2005 2006 2008 2011 Murine
More informationDocetaxel + Carboplatin + Trastuzumab
Docetaxel + Carboplatin + Trastuzumab Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy
Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy December 2007 This technology summary is based on information available at the time of research and
More informationRegimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.
Palliative Breast Cancer Regimens The following table lists the evidence-informed regimens (both IV and non-iv) for breast cancer used in the palliative setting. It is expected that the prescribing oncologist
More informationNCCP Chemotherapy Regimen. DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH)
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel
More informationReview of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012
Review of adjuvant and neo-adjuvant abstracts from SABCS 2011 January 7 th 2012 Ruth M. O Regan, MD Professor and Vice-Chair for Educational Affairs, Department of Hematology and Medical Oncology, Emory
More information亞東紀念醫院 Breast Cancer 化學治療處方集
亞東紀念醫院 Breast Cancer 化學治療處方集 2008-08 制定 最近修改日期 :2015-01 CMF Breast cancer 化學治療處方參考集 Adjuvant Classic CMF Cyclophosphamide 100mg/m2 PO qd; D1-D14 Methotrexate 40mg/m 2 in N/S 100 ml IV drip 30 mins; D1,
More informationBEVACIZUMAB (AVASTIN ) & Paclitaxel PROTOCOL
Bevacizumab (Avastin ) & Paclitaxel The treatment of Advanced Breast Cancer DRUG ADMINISTRATION Da Drug Daily Dose Route Diluent & Rate y 250mls Sodium Day 1,15 Bevacizumab 10 mg/kg Infusion Chloride 0.9%*
More informationBevacizumab + Paclitaxel & Carboplatin
Bevacizumab + Paclitaxel & Carboplatin Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from NHS England Cancer
More informationHerceptin SC (Subcutaneous Trastuzumab)
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Rate 1 Herceptin SC (trastuzumab) 600mg S/C 2 to 5 mins *PRECAUTION: In order to reduce the risk of medication errors it is recommended that all trastuzumab
More informationThames Valley. Thames Valley Chemotherapy Regimens Breast Cancer
Chemotherapy Regimens Breast Cancer Notes from the editor These regimens are available on the Network website www.tvscn.nhs.uk Any correspondence about the regimens should be addressed to: Sally Coutts,
More informationNCCP Chemotherapy Regimen
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (175) 14 day and Trastuzumab Therapy (DD AC-TH) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationTreatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic Therapy
Women s Empowerment Cancer Advocacy Network (WE CAN) Conference Bucharest, Romania October 2015 Treatment Options for Breast Cancer in Low- and Middle-Income Countries: Adjuvant and Metastatic Systemic
More informationTRANSPARENCY COMMITTEE OPINION. 15 February 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 15 February 2006 Taxotere 20 mg, concentrate and solvent for solution for infusion B/1 vial of Taxotere and 1 vial
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationBevacizumab + Paclitaxel + Cisplatin
Bevacizumab + Paclitaxel + Cisplatin Available for Routine Use in Not routinely commissioned, each case requires prior documented approval before offering & commencing therapy from the Cancer Drugs Fund
More informationHerceptin IV (Trastuzumab) and Paclitaxel Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Given as a three weekly schedule Day Drug Daily Dose Route Diluent & Rate On first cycle 250mls Normal Saline Herceptin IV 8 mg/kg Infusion only 90 mins On other 250mls Normal
More informationDERBY-BURTON LOCAL CANCER NETWORK FILENAME Peruse.DOC CONTROLLED DOC NO: CCPG R29
Pertuzumab + Trastuzumab + Docetaxel (Peruse study) A Multicenter, open-label, single arm study of Pertuzumab in combination with Trastuzumab and a Taxane in first-line treatment of patients with HER2-positive
More informationGuidelines for the Use of Anti-Emetics with Chemotherapy
Guidelines for the Use of Anti-Emetics with The purpose of this document is to provide guidance on the rational use of anti-emetics for prevention and treatment of chemotherapy-induced nausea and vomiting
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Everolimus in combination with exemestane for the treatment of advanced or metastatic HER2 negative, oestrogen
More informationNadia Harbeck Breast Center University of Cologne, Germany
Evidence in Favor of Taxane Based Combinations and No Anthracycline in Adjuvant and Metastatic Settings Nadia Harbeck Breast Center University of Cologne, Germany Evidence in Favor of Taxane Based Combinations
More informationNeo-adjuvant and adjuvant treatment for HER-2+ breast cancer
Neo-adjuvant and adjuvant treatment for HER-2+ breast cancer Angelo Di Leo «Sandro Pitigliani» Medical Oncology Unit Hospital of Prato Istituto Toscano Tumori Prato, Italy NOAH: Phase III, Open-Label Trial
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationBreast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer
Breast Pathway Group Epirubicin & Cyclophosphamide x 4 followed by Carboplatin & Paclitaxel x 4 for Early Breast Cancer Indication: Neoadjuvant therapy for patients with BRCA1/2 mutations EC Regimen details:
More informationAdjuvant Chemotherapy + Trastuzumab
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Chemotherapy + Trastuzumab (Optimal Drugs / Dosage / Trastuzumab) Adjuvant Chemotherapy (Optimal Drugs / Optimal Dosage
More informationNCCP Chemotherapy Regimen
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast
More informationPerjeta (pertuzumab)
Perjeta (pertuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201809/16/2018 POLICY A. INDICATIONS The indications
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationDoxorubicin and Ifosfamide Sarcoma
Systemic Anti Cancer Treatment Protocol Doxorubicin and Ifosfamide Sarcoma PROTOCOL REF: MPHADOXIFO (Version No:.0) Approved for use in: Soft tissue sarcoma Dosage: Drug Dosage Route Frequency Doxorubicin
More informationNCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T)
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLitaxel (80) 7 day Therapy (DD AC-T) INDICATIONS FOR USE: INDICATION Adjuvant Treatment of High Risk Node Negative or Node Positive
More informationClinical Expert Submission Template
Clinical Expert Submission Template Thank you for agreeing to give us a personal statement on your view of the technology and the way it should be used in the NHS. Health care professionals can provide
More informationNab-Paclitaxel (Abraxane) and Gemcitabine For Pancreatic Adenocarcinoma Cumbria, Northumberland, Tyne & Wear Area Team
DRUG ADMINISTRATION SCHEDULE Day Drug Dose Route Diluent & Rate 1 8 15 Sodium Chloride 0.9% 100ml Infusion Fast Running Dexamethasone 8mg Oral Ondansetron 8mg Oral/ IV Chlorphenamine 10mg Intravenous Slow
More informationBEVACIZUMAB (AVASTIN ), CARBOPLATIN & PACLITAXEL for Ovarian Cancer
DRUG ADMINISTRATION Day Drug Dose Route Diluent & Rate Day 1 Sodium Chloride 0.9% 250/500ml Infusion Fast Running Dexamethasone See Below* Chlorphenamine 10mg Intravenous Slow bolus Ranitidine 50mg Intravenous
More informationLung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Carboplatin & PO Vinorelbine in Non-Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in
More informationTrastuzumab (IV) Monotherapy - 7 days
INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital
More informationBreast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer
Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x Indication: Neoadjuvant or adjuvant therapy for moderate to high risk node positive breast
More informationBC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN)
BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician BRAJDCARBT Breast Dr. Susan Ellard
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationEC TH s/c Neoadjuvant Breast Cancer
EC TH s/c Neoadjuvant Breast Cancer Background: Neoadjuvant chemotherapy for inoperable locally advanced, inflammatory breast cancer or to downsize tumour prior to surgery. For patients with HER 2 positive
More informationCarboplatin, Paclitaxel and Bevacizumab (gynae)
Carboplatin, Paclitaxel and Bevacizumab (gynae) Indication First line treatment of recurrent or metastatic cervical cancer. WHO performance status 0 or 1. First line treatment of advanced epithelial ovarian,
More informationPaclitaxel Gastric Cancer
Systemic Anti Cancer Treatment Handbook Paclitaxel Gastric Cancer PROTOCOL REF: MPHAUGIPAC (Version No: 1.0) Approved for use in: Second line treatment of locally advanced and metastatic gastric / gastro-oesophageal
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationCancer du sein métastatique et amélioration de la survie Pr. X. Pivot
Cancer du sein métastatique et amélioration de la survie Pr. X. Pivot Date of preparation: November 2015. EU0250i TTP/PFS Comparaisons First line metastatic breast cancer Monotherapy Docetaxel Chan 1999
More informationLapatinib and Capecitabine Therapy
Lapatinib and Capecitabine Therapy This protocol should be read in conjunction with NCCP protocol 00216 Capecitabine Monotherapy. INDICATIONS FOR USE: INDICATION Treatment of adult patients with breast
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationPositive HER-2 tumor. How to incorporate the new drugs into neoadjuvance
Oncology Department Vall d Hebron University Hospital Barcelona. Spain Positive HER-2 tumor. How to incorporate the new drugs into neoadjuvance Javier Cortés June/2013 MD Anderson experience Buzdar et
More informationNCCP Chemotherapy Regimen
DOXOrubicin, Cyclophosphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) Therapy (AC-T) Note: There is an option for Dose Dense DOXOrubicin, cyclophosphamide PACLitaxel (DD AC T) therapy described
More informationNCCP Chemotherapy Protocol. Nab-Paclitaxel (Abraxane ) Monotherapy 21 day cycle
Nab-Paclitaxel (Abraxane ) Monotherapy 21 day cycle INDICATIONS FOR USE: INDICATION Treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and
More informationFEC-TPH (Fluorouracil, Epirubicin and Cyclophosphamide) followed by Docetaxel, Pertuzumab and Trastuzumab (Herceptin )
FEC-TPH (Fluorouracil, Epirubicin and Cyclophosphamide) followed by Docetaxel, Pertuzumab and Trastuzumab (Herceptin ) Indication Neo-adjuvant treatment for HER2 positive, locally advanced, inflammatory
More informationTrastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment
Trastuzumab (Herceptin) for HER2 positive early, locally advanced and inflammatory breast cancer neoadjuvant treatment August 2010 This technology summary is based on information available at the time
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationCASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD
CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen
More informationPERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES
PERJETA (pertuzumab) FOR TREATMENT OF MALIGNANCIES Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures,
More informationTherapy Side Effects
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Therapy Side Effects Therapy Side Effects Versions 2004 2011: Albert / Bischoff / Costa / Friedrichs / Göhring / Jackisch/
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationNCCP Chemotherapy Regimen. Pertuzumab and Trastuzumab and DOCEtaxel Therapy - 21 day cycle
Pertuzumab and Therapy - 21 day cycle INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Indicator Pertuzumab is indicated in combination with trastuzumab and DOCEtaxel in adult patients
More informationTRANSPARENCY COMMITTEE OPINION. 29 April 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 29 April 2009 NAVELBINE 20 mg, soft capsules B/1 (CIP: 365 948-4) NAVELBINE 30 mg, soft capsules B/1 (CIP: 365 949-0)
More informationGemcitabine + Cisplatin Regimen
Gemcitabine + Cisplatin Regimen Available for Routine Use in Burton in-patient Derby in-patient Burton day-case Derby day-case Burton community Derby community Burton out-patient Derby out-patient Indication
More informationLung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & PO Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationCisplatin Vinorelbine (Oral) therapy +/- radiotherapy
1 REGIMEN TITLE: Cisplatin Vinorelbine (Oral) therapy +/- radiotherapy Page 1 of 5 Indication: First line in Radical/ Induction, Adjuvant and Advanced & Palliative treatment of Non-small cell lung cancer
More informationCisplatin and Gemcitabine Bladder Cancer: Full and split dose
Systemic Anti Cancer Treatment Protocol Cisplatin and Gemcitabine Bladder Cancer: Full and split dose PROCTOCOL REF: MPHAUROCIG (Version No: 1.0) Approved for use in: Neoadjuvant and palliative indications
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationCarboplatin / Gemcitabine Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Carboplatin / Gemcitabine Gynaecological Cancer PROCTOCOL REF: MPHAGYNCAG (Version No: 1.0) Approved for use in: Recurrent/metastatic endometrial carcinoma Previously
More informationCisplatin Doxorubicin Sarcoma
Systemic Anti Cancer Treatment Protocol Cisplatin Doxorubicin Sarcoma PROCEDURE REF: MPHACISDOX (Version No. _1.0) Approved for use in: Osteosarcoma Palliative / advanced disease Not suitable for PAM schedule
More informationCycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline
BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:
More informationBreast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Cancer
Breast Pathway Group EC x 4 Docetaxel x 4: Epirubicin & Cyclophosphamide followed by Docetaxel in Early Breast Indication: Neoadjuvant therapy for high risk and fit breast cancer patients suitable for
More informationNew Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More informationNCCP Chemotherapy Regimen. Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T)
Dose Dense DOXOrubicin, Cyclophosphamide (AC 60/600) 14 day followed by PACLItaxel (175) 14 day Therapy (DD AC-T) Note: There is an option for DOXOrubicin, cyclophosphamide followed by weekly PACLItaxel
More information新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方
新竹馬偕紀念醫院癌症中心 乳癌化學治療藥物處方 文件修訂記錄 修正次數 修正日期 修正版別 修 改 內 容 1 2011.04.07 1.0 初次訂定 2 2013.05.08 2.0 修訂 3 2013.04.30 3.0 修訂 :Triple-Negative Breast Cancer 處方 新增 :Neoadjuvant-p7~8 4 2014.04.29 4.0 修訂 :FEC + Trastuzumab
More informationBurkitt s Lymphoma or DLBCL with adverse features PATIENTS WITH GOOD PERFORMANCE STATUS
Regimen R-CODOX M Indication Burkitt s Lymphoma or DLBCL with adverse features Therapeutic Intent Radical/Curative PATIENTS WITH GOOD PERFORMANCE STATUS Day Medication Dose Route Administration Details
More informationHaematology, Oncology and Palliative Care Directorate.
Anticancer Treatment for Administration on the Somerset Mobile Chemotherapy Unit The table below details the suitability of different types of anticancer treatment for administration on the Somerset Mobile
More informationCommon disease 175,000 new cases/year 44,000 deaths/year Less than 10% with newly diagnosed at presentation have stage IV disease Chronic disease,
Chemotherapy for Metastatic Breast Cancer: Recent Results HARMESH R. NAIK, MD. Karmanos Cancer Institute and St. Mary Hospital Metastatic breast cancer (MBC) Common disease 175,000 new cases/year 44,000
More informationOncological Treatment of Breast Cancer
Oncological Treatment of Breast Cancer Pathway of Care Core Network Team Publication date October 2017 Expected review date October 2019 Version number 22 Version status Final Table of Contents 1.0 ONCOLOGY
More informationNCCP Chemotherapy Regimen. DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days
DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days INDICATIONS FOR USE: INDICATION ICD10 Regimen Code *Reimbursement Status Adjuvant treatment HER2 positive early breast cancer C50 00258a Hospital
More informationFludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study
Fludarabine + Cyclophosphamide + Rituximab (FCR) - FLAIR Study Front-Line therapy in CLL: Assessment of Ibrutinib-containing Regimes. ***See protocol for further details*** Available for Routine Use in
More informationLung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC)
Lung Pathway Group Cisplatin & IV Vinorelbine in Non- Small Cell Lung Cancer (NSCLC) Indication: First line in radical/induction treatment in locally advanced NSCLC First line palliative treatment in advanced/metastatic
More informationTHE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST. Systemic Anti Cancer Treatment Protocol. EDP + mitotane
Systemic Anti Cancer Treatment Protocol EDP + mitotane PROCEDURE REF: MPHAHANEDP (Version No: 1.0) Approved for use in: Symptomatic treatment for advanced (unresectable, metastatic or relapsed) adrenocortical
More informationBRAVTPCARB. Protocol Code: Breast. Tumour Group: Dr. Karen Gelmon. Contact Physician:
BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN), PACLitaxel and CARBOplatin as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour
More informationThe next wave of successful drug therapy strategies in HER2-positive breast cancer. Hans Wildiers University Hospitals Leuven Belgium
The next wave of successful drug therapy strategies in HER2-positive breast cancer Hans Wildiers University Hospitals Leuven Belgium Trastuzumab in 1st Line significantly improved the prognosis of HER2-positive
More informationVincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma
Systemic Anti Cancer Treatment Protocol Vincristine Ifosfamide Doxorubicin Etoposide (VIDE) Sarcoma PROTOCOL REF: MPHAVIDE (Version No: 1.0) Approved for use in: Ewings sarcoma Desmoplastic small round
More informationContents Trials. Dose guidelines. Calvert formula Issue Date: January Author: No: Copy. Pagee 1 of 21. Issue.
Chapter 1: General information Contents Chapter 1: General information... 1 General observations... 2 Protocol Additions 2013... 2 Cancer Drugs Fund... 2 Off Protocol Treatment Policy... 2 Trials... 2
More informationHER2-positive Breast Cancer
HER2-positive Breast Cancer Multiple choices what to use when? Thomas Ruhstaller Brustzentrum St. Gallen Adjuvant setting NCIC MA5 N Engl J Med 06, 2103 6 x CEF can 6 x CMF oral HER2 + pg schlecht in allen
More informationPaclitaxel Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol Paclitaxel Gynaecological Cancer PROTOCOL REF: MPHAGYNPAC (Version No: 1.0) Approved for use in: Second/ third line option for advanced ovarian cancers (3 weekly
More informationFEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel)
FEC-T (Fluorouracil, Epirubicin and Cyclophosphamide and Docetaxel) Indication Adjuvant or neo-adjuvant treatment for high risk early and locally advanced breast cancer. (NICE CG80) ICD-10 codes Codes
More informationR-IDARAM. Dexamethasone is administered as an IV infusion in 100mL sodium chloride 0.9% over 30 minutes.
R-IDARAM Indication Secondary CNS lymphoma ICD-10 codes Codes with a prefix C85 Regimen details Day Drug Dose Route 1 Rituximab 375mg/m 2 IV infusion 1 Methotrexate 12.5mg Intrathecal 1 Cytarabine 70mg
More information